Medpace Holdings (XTER:01P) 1-Year Sharpe Ratio: N/A (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:01P Medpace Holdings Inc XTER:01P
96 GF Score
Price €524.00
GF Value €462.90
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-29), Medpace Holdings's 1-Year Sharpe Ratio is Not available.

Medpace Holdings  (XTER:01P) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Medpace Holdings 1-Year Sharpe Ratio Related Terms

XTER:01P vs : 1-Year Sharpe Ratio Comparison

For the Diagnostics & Research subindustry, Medpace Holdings's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medpace Holdings 1-Year Sharpe Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's 1-Year Sharpe Ratio falls into.


XTER:01P
96GF Score
Medpace Holdings Inc XTER:01P
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Is Medpace Holdings (XTER:01P) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of €524.00 is trading 13.2% above its estimated GF Value™ of €462.90. GuruFocus considers Medpace Holdings to be Modestly Overvalued.

Key valuation signals for XTER:01P:

  • 1-Year Sharpe Ratio: N/A
  • GF Value™: €462.90 vs. price of €524.00 (13.2% above fair value)
  • GF Score™: 96/100 with 2 warning signs

No single metric tells the full story. See the XTER:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medpace Holdings Business Description

Comparable Companies
Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
96GF Score

Get the complete analysis for XTER:01P

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€524.00
Price
€462.90
GF Value